MedTrace Logo

Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer

NCT03451812 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2019-08-08

No results posted yet for this study

Summary

Primary objective:

To correlate the blood/urine metabolomic biomarkers with PET/MR imaging.

Secondary objectives:

1. To evaluate the sensitivity and specificity of the PET/MR in diagnosis of prostate cancer.
2. To examine the diagnostic performance among subgroups of defined high-risk and low-risk subjects.
3. To interrogate the metabolomic alterations with the molecular PET/MR to develop workable panel biomarkers.

Conditions

  • Prostate Adenocarcinoma

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Gigin Lin, MD, PhD · Medical Imaging and Intervention, Chang Gung Memorial Hospital

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03451812 on ClinicalTrials.gov